相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease
John A. Dougherty et al.
ANNALS OF PHARMACOTHERAPY (2021)
A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
Philip N. Newsome et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus
Lee-Lee Lai et al.
DIGESTIVE DISEASES AND SCIENCES (2020)
Comparing point shear wave elastography (ElastPQ) and transient elastography for diagnosis of fibrosis stage in non-alcoholic fatty liver disease
Wai Ling Leong et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2020)
Long-term outcomes of non-alcoholic fatty liver disease and the risk factors for mortality and hepatocellular carcinoma in a Japanese population
Tomomi Kogiso et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2020)
Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis
Yoshio Sumida et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, open-label, three-arm, active control study
Tomoe Kinoshita et al.
JOURNAL OF DIABETES INVESTIGATION (2020)
Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease
Masanori Shimizu et al.
DIABETES OBESITY & METABOLISM (2019)
Effect of luseogliflozin on hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective, single-arm trial (LEAD trial)
Yoshio Sumida et al.
HEPATOLOGY RESEARCH (2019)
The Long-term Efficacy of Sodium Glucose Co-transporter 2 Inhibitor in Patients with Non-alcoholic Fatty Liver Disease
Mio Yamashima et al.
INTERNAL MEDICINE (2019)
Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease
Mitsuko Inoue et al.
JOURNAL OF DIABETES INVESTIGATION (2019)
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
Naga Chalasani et al.
HEPATOLOGY (2018)
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Zobair Younossi et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2018)
Treating nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a review of efficacy and safety
Elizabeth P. Mills et al.
THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM (2018)
Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)
Mohammad Shafi Kuchay et al.
DIABETES CARE (2018)
Efficacy of canagliflozin against nonalcoholic fatty liver disease: a prospective cohort study
Toshio Itani et al.
OBESITY SCIENCE & PRACTICE (2018)
Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective randomized controlled pilot study
Takashi Shibuya et al.
DIABETES OBESITY & METABOLISM (2018)
Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus
Yuya Seko et al.
HEPATOLOGY RESEARCH (2017)
Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD
Hannes Hagstrom et al.
JOURNAL OF HEPATOLOGY (2017)
Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial
Daisuke Ito et al.
DIABETES CARE (2017)
Meta-Analysis of Randomized Controlled Trials of Pharmacologic Agents in Non-alcoholic Steatohepatitis
Adnan Said et al.
ANNALS OF HEPATOLOGY (2017)
AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions
Amedeo Lonardo et al.
DIGESTIVE AND LIVER DISEASE (2017)
Which treatment for type 2 diabetes associated with non-alcoholic fatty liver disease?
Arianna Mazzotti et al.
DIGESTIVE AND LIVER DISEASE (2017)
Effects of a Sodium-Glucose Cotransporter 2 Inhibitor in Nonalcoholic Fatty Liver Disease Complicated by Diabetes Mellitus: Preliminary Prospective Study Based On Serial Liver Biopsies
Norio Akuta et al.
HEPATOLOGY COMMUNICATIONS (2017)
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus A Randomized Trial
Kenneth Cusi et al.
ANNALS OF INTERNAL MEDICINE (2016)
Effect of Weight Loss, Diet, Exercise, and Bariatric Surgery on Nonalcoholic Fatty Liver Disease
William N. Hannah et al.
CLINICS IN LIVER DISEASE (2016)
Liver Stiffness in Nonalcoholic Fatty Liver Disease: A Comparison of Supersonic Shear Imaging, FibroScan, and ARFI With Liver Biopsy
Christophe Cassinotto et al.
HEPATOLOGY (2016)
Global Epidemiology of Nonalcoholic Fatty Liver Disease-Meta-Analytic Assessment of Prevalence, Incidence, and Outcomes
Zobair M. Younossi et al.
HEPATOLOGY (2016)
EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
Giulio Marchesini et al.
JOURNAL OF HEPATOLOGY (2016)
The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice
Yasushi Honda et al.
PLOS ONE (2016)
Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction
Chikara Komiya et al.
PLOS ONE (2016)
Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease
Paul Angulo et al.
GASTROENTEROLOGY (2015)
Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
Sumio Watanabe et al.
JOURNAL OF GASTROENTEROLOGY (2015)
Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea A 52-week randomized trial
Guntram Schernthaner et al.
DIABETES CARE (2013)
A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes
E. Ferrannini et al.
DIABETES OBESITY & METABOLISM (2013)
Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial
William T. Cefalu et al.
LANCET (2013)
NAFLD in Asia-as common and important as in the West
Geoffrey C. Farrell et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2013)
Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis
Rohit Loomba et al.
HEPATOLOGY (2012)
Impact of glucose tolerance on the severity of non-alcoholic steatohepatitis
Akinobu Nakamura et al.
JOURNAL OF DIABETES INVESTIGATION (2011)
Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis
M. O. Rakoski et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2010)
Diagnosis of Fibrosis and Cirrhosis Using Liver Stiffness Measurement in Nonalcoholic Fatty Liver Disease
Vincent Wai-Sun Wong et al.
HEPATOLOGY (2010)
A Meta-Analysis of Randomized Trials for the Treatment of Nonalcoholic Fatty Liver Disease
Giovanni Musso et al.
HEPATOLOGY (2010)
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis.
Arun J. Sanyal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD)
M. Yoneda et al.
DIGESTIVE AND LIVER DISEASE (2008)
Transient elastography for measurement of liver stiffness measurement can detect early significant hepatic fibrosis in Japanese patients with viral and nonviral liver diseases
Noriyuki Obara et al.
JOURNAL OF GASTROENTEROLOGY (2008)
Nonalcoholic fatty liver disease: From steatosis to cirrhosis
GC Farrell et al.
HEPATOLOGY (2006)
分享论文
